Two medicines, side by side
Mirabegron vs tolterodine
Mirabegron and tolterodine are both labeled for overactive bladder. Drugs@FDA records approvals of mirabegron since 2012 and of tolterodine since 1998. Pharmacies paid $9.39 per mirabegron ER 50 mg tablet and $0.268 per tolterodine tart ER 2 mg capsule (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. In FDA's classes, mirabegron is a beta3-adrenergic agonist and tolterodine a cholinergic muscarinic antagonist.
Check it at the source: the mirabegron FDA label on DailyMed (effective December 24, 2025); the tolterodine FDA label on DailyMed (effective February 9, 2026).
Highlights of the mirabegron record
Mirabegron (Myrbetriq) · label of December 24, 2025
Used for
From the label: indicationsMirabegron extended-release tablets are beta-3 adrenergic agonist indicated for the treatment of: Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. […]
On the market
- Earliest approval on file
- June 28, 2012
- Generic labelers
- 8 labelers
- Pharmacy cost
- $9.39 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 1
Highlights of the tolterodine record
Tolterodine (Detrol) · label of February 9, 2026
Used for
From the label: indicationsTolterodine tartrate extended-release capsules are an antimuscarinic indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. ( 1 ) Tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [ see CLINICAL STUDIES ( 14 ) ].
On the market
- Earliest approval on file
- March 25, 1998
- Generic labelers
- 14 labelers
- Pharmacy cost
- $0.268 per capsule
Supply and safety
- Shortage
- No current entry
- Recalls
- 4
Source: FDA drug labels via openFDA (Mirabegron label of December 24, 2025, Tolterodine label of February 9, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do mirabegron and tolterodine differ on the record?
In FDA's classes, mirabegron is a beta3-adrenergic agonist and tolterodine a cholinergic muscarinic antagonist.
Generics: mirabegron since 2019; tolterodine since 2012 (Drugs@FDA).
| Mirabegron | Tolterodine | |
|---|---|---|
| Labeled for | Overactive bladder | Overactive bladder |
| Pharmacologic class | beta3-Adrenergic Agonist | Cholinergic Muscarinic Antagonist |
| How it works (label) | Mirabegron is an agonist of the human beta-3 adrenergic receptor (AR) as demonstrated by in vitro laboratory experiments using the cloned human beta-3 AR. | n/a |
| Half-life (label) | Elimination Mirabegron Extended-Release Tablets Monotherapy for Adult OAB: The terminal elimination half-life (t 1/2 ) of mirabegron is approximately 50 hours in patients. | n/a |
| Earliest approval on file (Drugs@FDA) | June 28, 2012 | March 25, 1998 |
| First generic approved | December 27, 2019 | September 25, 2012 |
| Generic labelers (NDC) | 8 labelers | 14 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $9.39 per tablet (Mirabegron ER 50 mg tablet) | $0.268 per capsule (Tolterodine tart ER 2 mg capsule) |
| 12-month price change | -2% | -27% |
| Boxed warning | No | No |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 1 | 4 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 38,466 | 12,383 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What do the labels say about using others of their kind?
Tolterodine label, drug interactionsConcomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects.
Source: FDA drug labels via openFDA
What next?
- Alternatives to mirabegron
- every medicine labeled for the same conditions